Background. Pseudomonas aeruginosa is a key respiratory pathogen in people with cystic fibrosis (CF). Due to its association with lung disease progression, initial detection of P. aeruginosa in CF respiratory cultures usually results in antibiotic treatment with the goal of eradication. Pseudomonas aeruginosa exhibits many different phenotypes in vitro that could serve as useful prognostic markers, but the relative relationships between these phenotypes and failure to eradicate P. aeruginosa have not been well characterized.
the best-known change is the emergence of a colony phenotype known as mucoidy [14] . Previous studies indicated that mucoidy is rare among environmental or non-CF Pa [15] and in early CF [16] , but emerges on average after approximately 11 years of infection [14] . Mucoidy has also been associated with more severe lung disease [14, 17] . Recently, inactivating mutations in lasR, which encodes a transcriptional regulator in an intercellular signaling pathway known as quorum sensing, have also been shown to occur frequently during chronic CF Pa infections [10, 18, 19] . Prior studies indicated that lasR mutations occurred earlier on average than mucoidy and were associated with more severe lung disease [19] . Decreases in antibiotic susceptibilities [20] and altered production of the pigment pyocyanin [21] were also associated with advanced age and lower lung function in studies focused on those phenotypes. Many other Pa adaptive changes, including alterations in cell motility, metabolism, virulence, DNA mismatch repair, and secreted molecule production, have been identified [11] [12] [13] , but less is known about their relationships with clinical outcomes. Moreover, few studies have compared the prognostic values of different Pa phenotypes [22, 23] .
The advent of newborn screening for CF has enabled early surveillance for Pa infection and the prompt initiation of antibiotic eradication therapy upon Pa detection. The ability to predict failure of eradication by measuring characteristics of Pa isolates from early infection is therefore of interest. One previous study attempted to correlate Pa phenotypes at initial detection with eradication after antibiotic treatments, but no predictive characteristics were identified [22] . In addition, in vitro antibiotic susceptibilities have been shown not to correlate with Pa eradication after antimicrobial therapy [22, 23] . These studies highlight the need for clinically useful predictors of eradication, which could identify patients who might benefit from more aggressive initial antibiotic treatment.
A recent multicenter clinical trial, the Early Pseudomonas Infection Control (EPIC) clinical trial [24] , compared different antibiotic eradication strategies for newly identified Pa among children with CF. Children aged 1-12 years were randomized to receive 1 of 2 antipseudomonal antibiotic regimens and were followed for 18 months, with the goal of comparing safety and efficacy between regimens. The trial demonstrated comparable effectiveness across all endpoints between antibiotic treatment strategies, including successful Pa eradication for up to 18 months after initial antibiotic therapy [24] . However, 34% of trial participants failed to eradicate Pa, with a subsequent Pa-positive culture after the initial antibiotic course and during the remainder of the 18-month trial. Further studies in this subject group could not identify baseline clinical factors or patterns of infection that predicted eradication failure [25] . This study presented an ideal opportunity to determine whether there are Pa characteristics that correlate with poor microbiologic and clinical outcomes.
We therefore characterized the baseline Pa isolates from participants enrolled in the EPIC clinical trial using a panel of 22 in vitro phenotypic tests, which we selected both for prior evidence that they exhibit adaptive change in CF and because they were simple and reproducible in high-throughput format. Our aim was to identify a panel of useful, easily measured tests that could potentially be used clinically to predict failure to eradicate after antimicrobial therapy.
METHODS

Cohort Selection
The study cohort was comprised of participants from the EPIC clinical trial (Figure 1 ) (ClinicalTrials.gov: NCT00097773) [24] . All participants with isolates from the screening visit or from the 6 months prior to enrollment ("baseline" isolates) were included in this study. This study was approved by the institutional review board at Seattle Children's Hospital. Complete details regarding the study cohort and study design are in the Supplementary Data.
Study Endpoints
The primary endpoint was time to Pa eradication failure, defined as the first occurrence of a Pa-positive culture after the initial quarter of antipseudomonal antibiotic therapy. During the clinical trial, respiratory cultures (oropharyngeal or sputum) were obtained during follow-up at weeks 10, 22, 34, 46, 58, and 70 (<4% of children had sputum available at each visit). Secondary endpoints included the proportion of participants with emergent mucoid Pa and time to pulmonary exacerbation during the 15-month follow-up period. Details regarding the definitions of study endpoints, as well as culture processing, are in the Supplementary Data.
Phenotyping and Genotyping of Pa Isolates
All Pa clinical isolates collected at study sites were characterized centrally in 1 laboratory after minimal passaging. Phenotypic analysis and lasR gene sequencing were performed using tests found to be reproducible in multiple replicates and in highthroughput format, using quantitative measures (including for colorimetric analysis) when possible to minimize bias. Full details regarding these tests are included in the Supplementary Data.
Statistical Analysis
Details of the statistical analysis approaches for estimating the association between Pa isolate characteristics and clinical outcomes are described in the Supplementary Data.
RESULTS
Cohort Characteristics
Of the 304 trial participants, 194 of 304 (64%) had baseline Pa isolates available at the core microbiology laboratory (284 isolates total) and were included in the study cohort. Table 1 compares this participant subgroup with those with newly identified Pa positivity but who did not have baseline isolates available. No significant differences were found between participants with and without available baseline Pa isolates, although slightly more participants with first lifetime documentation of Pa had baseline isolates available (9% more; 95% confidence interval [CI] , −2% to 20%). Figure 2 displays the prevalence of each tested phenotypic characteristic among isolates from baseline cultures. Supplementary  Figures 1-4 display examples of phenotypes of particular relevance for this study. Besides wild-type tan colony color, pyocyanin production during in vitro liquid growth was the most prevalent assayed phenotype at baseline, present in 74 of 112 (66%) cultures. Mucoidy was exhibited in 17 of 194 (9%) baseline cultures and auxotrophy by 13 of 194 (7%) cultures. Defects in motility, including swimming (57/194 [29%]) and twitching (31/111 [28%]), were also relatively common among participants' baseline cultures. Defective production of the siderophore pigment pyoverdine was identified among 81 of 112 (72%) cultures. All of these phenotypes, which were variably but clearly common among the baseline isolates, have previously been associated with adaptation to the CF airway during chronic infection [12] .
Baseline Prevalence of Pa Phenotypic Characteristics
Because our previous work indicated a high prevalence of inactivating mutations in lasR early during chronic CF infections [10, 18, 19] and demonstrated associations of these mutations with worse lung disease and subsequent emergence of mucoidy [19] , we sequenced lasR among the baseline isolates. We also characterized several phenotypes shown previously to be conferred by inactivating lasR mutations [10, 19, 26] 
Concordance Between Pa Phenotypic Characteristics at Baseline
We characterized the relationships between pairs of assayed characteristics at baseline (Supplementary Table 1 ). The most significant findings of concordance between phenotypes occurred between colony sectoring and irregular colony edges 
Association Between Baseline Pa Phenotypic Characteristics and Failure to Eradicate After Antipseudomonal Therapy
Whereas the proportion of participants failing to achieve Pa eradication was 34% among the entire trial population, in this study cohort (ie, those for whom baseline isolates were available), 79 of 194 (41%) of participants failed to achieve Pa eradication during the study. Table 2 displays results from a multivariable model used to identify which baseline Pa phenotypic characteristics, independent of other baseline factors, were associated with failure to eradicate. As found in the original trial, antibiotic therapy received during the trial was not significantly associated with microbiologic and clinical outcomes in our study and was not included for adjustment in the final model. Wrinkly colony surface and irregular colony edges were each associated with significantly increased risk of failure to eradicate after antipseudomonal therapy. Figure 3 displays the corresponding Kaplan-Meier curves for these phenotypes. Sensitivity analyses indicated no other significant predictors of failure to eradicate, including coinfection with other organisms and past history of Pa (Table 2) . Wrinkly colonies and irregular colony edges (which were not significantly correlated with each other, Supplementary Table 1) remained the most significant predictors of failure to eradicate even after adjustment for these factors (Table 2 ). This sensitivity analysis was repeated among the subset of participants for whom baseline spirometry was available, yielding similar results.
Associations Between Baseline Pa Phenotypic Characteristics With Emergence of Mucoidy and Risk of Pulmonary Exacerbation
Because mucoidy has been associated with both chronic infection and poor outcomes [14, 17] , we determined whether baseline Pa characteristics were associated with subsequent emergence of mucoidy during the 18-month study follow-up period. The presence of either colony autolysis or sheen at baseline was the only characteristic significantly associated with subsequent emergence of mucoidy. A total of 4 of 31 participants (12.9%) with initial isolates exhibiting autolysis and/or sheen had new emergence of mucoid Pa during the trial, compared with 4 of 142 (2.8%) of those without either phenotype (10.1% difference; P = .035). No baseline Pa phenotypes were significantly associated with increased risk of pulmonary exacerbation during the follow-up (not shown).
Biofilm Formation
The 2 colony phenotypes associated with failure to eradicate after antibiotic treatment, wrinkly colony surface and irregular colony edges, have both been associated with enhanced biofilm formation [10, 27, 28] , suggesting a mechanistic link between these colony phenotypes that could indicate their pathophysiologic significance. However, because in vitro biofilm testing is complex and lacks the reproducibility required for highthroughput analysis, we tested a subset of isolates (n = 19 isolates each with wrinkly surface, irregular edges, or neither; total n = 57) with these characteristics for their biofilm-forming abilities in vitro. We found no association between in vitro biofilm formation and either wrinkly colony surface or irregular colony edges (data not shown).
DISCUSSION
In contrast to previous reports and traditionally held concepts [14, 28, 29, 30] , we found that several Pa in vitro phenotypes commonly considered to represent adaptation during chronic infection occurred frequently among newly identified Pa isolates from children with CF. With the goal of identifying candidate prognostic markers of failure of antibiotic eradication, we assayed phenotypes chosen for prior evidence of undergoing change during chronic CF infections and for their reproducibility, definitive endpoints, and ease of measurement in clinical laboratory settings. Two of these phenotypes, wrinkly colony surface and irregular colony edges, were significantly associated with subsequent failure to eradicate after antibiotic treatment. These results suggest that Pa isolated from CF respiratory samples during early infection may represent lineages that have adapted to that host ( perhaps in the upper airways, or undetected in the lower respiratory tract) or to another host or environment prior to acquisition. If our results are validated, these 2 easy-to-identify colony phenotypes may serve as prognostic markers of eradication failure, potentially identifying patients who may benefit from more aggressive eradication treatment. A previous study attempted to relate phenotypic characteristics of CF Pa isolates from initial detection with subsequent eradication failure [22] . That study included 52 infection events, focusing on patients with either persistent or eradicated infection, and excluding patients with intermittent Pa detection post-antibiotic treatment. The 9 characteristics examined, in contrast to the 22 assays used here, were generally chosen to represent potential determinants of pathogenicity or antibiotic resistance (eg, cytotoxicity, production of virulence factors, in vitro susceptibilities, and mutation frequencies), rather than prior evidence of adaptive change or clinical utility. The authors found that eradicated isolates were less likely to be cytotoxic than were baseline isolates from persistent infection, but they concluded that it was not possible to predict eradication failure using those tests.
In the current study, mucoidy, an in vitro phenotype traditionally associated with failure of antibiotic treatment, was not significantly associated with eradication failure. This finding contrasts with an earlier study examining aerosolized tobramycin in treating Pa infection among 31 CF patients, which reported that eradication was significantly less likely in patients with mucoid isolates [23] . Those results likely differed from ours because the prior study did not focus exclusively on early infection. Similarly, another study of longitudinally collected Pa isolates identified decreased exoproduct production and decreased motility among isolates from persistent compared with cleared infections [13] . Because that study did not focus on newly detected Pa, those results could also reflect chronic infection.
Our results showed a surprisingly high baseline prevalence of phenotypes traditionally associated with adaptive change during chronic infection [31] , including mucoidy [14, 16] , defective motility [32] , and altered quorum sensing [18, 19] . These "early" isolates could represent adaptation of previously undetected infection in either the upper [13, 33, 34] or lower airways, despite negative cultures; because 94% of specimens in this study were from the oropharynx rather than sputum, our ability to detect lower airway infection was limited [35] . Alternatively, these findings may represent patient-to-patient transmission of preadapted lineages, a possibility that seems unlikely based on previous work suggesting acquisition from environmental sources [12] .
In CF, mucoidy has been associated with failure to eradicate with antibiotics [23] . Previous work suggested that mucoidy tends to emerge after an average of a decade of chronic infection [14, 19] , a change traditionally interpreted to reflect a chronic infection phenotype [1, 12] . Our finding that early Pa isolates from 9% of participants exhibited mucoidy not significantly associated with failure to eradicate after antibiotics raises questions about the prognostic significance of this phenotype in early infection. We also confirmed and extended our previous study results [19] that autolysis and/or sheen (indicators of LasR inactivation [10] ) preceded the emergence of mucoidy. Additional larger longitudinal studies will be required to clarify the natural history of Pa adaptive changes and the relative prognostic utility of each characteristic with respect to long-term clinical outcomes.
The 2 colony phenotypes that were associated with failure to eradicate after antibiotics, wrinkly colony surface and irregular colony edges, have both been associated previously with altered quorum sensing and increased biofilm formation [27, 28] , suggesting these colony phenotypes could be markers for 1 or both of these other characteristics. However, we did not identify associations between these colony phenotypes and either in vitro biofilm formation or lasR mutation. Therefore, the mechanism with which isolates with these phenotypes persist, if any, is not yet clear, and the prognostic utility of these phenotypes in predicting failure of eradication must be confirmed in a prospective study.
Prior work demonstrated that in vitro antibiotic susceptibilities of Pa isolates correlate poorly with subsequent CF clinical outcomes [36] , including eradication with antibiotics [22, 23] . Thus, we did not include susceptibility testing. Similarly, we did not assay other Pa characteristics found previously to change during chronic CF infections, either due to difficulty adapting those assays for high-throughput testing, expense, or poor reproducibility. Among these characteristics are type III secretion and cytotoxicity, metabolic changes, growth in sputum or under anaerobic conditions, hypermutability, membrane changes, and serum sensitivity [9, 11, 12] . We also only assayed biofilm formation on a subset of isolates due to issues with assay complexity and reproducibility. These characteristics represent potential future study possibilities.
There are several potential limitations of this work. For instance, recent studies showed that traditional culture methods (ie, isolating a small number of morphologically different bacterial colonies) frequently underrepresent the Pa diversity in individual samples of CF respiratory secretions during chronic infection with respect to antibiotic susceptibilities [37] , quorum sensing [38] , and other phenotypes [39, 40] . A second limitation is that study participants with lifetime histories of Pa positivity must have had a 2-year history of Pa-negative cultures, but required only 1 culture result in each of the 2 years. Although it is possible that participants with a lifetime history of Pa with fewer cultures during those 2 years could have been found to have more advanced Pa infection if sampled more frequently, our analyses did not identify associations between lifetime Pa history and any outcome of interest. Last, while this study is, to our knowledge, the largest comparative phenotypic analysis of its kind, the sample size may still have been insufficient to identify some relationships with failure to eradicate, emergence of mucoidy, or exacerbations. Additional study of larger isolate collections may clarify this issue.
In conclusion, we found that 2 easily identified Pa colony phenotypes, wrinkly colony surface and irregular colony edges, were associated with subsequent eradication failure. In addition, the in vitro phenotypes exhibited by baseline isolates suggest that Pa may have already adapted to host environments by the time it is first detected. Further studies of the predictive utility of these phenotypes are required to confirm these findings and to determine whether these phenotypes correlate with longer-term clinical outcomes.
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